OBJECTIVE:To study the status quo of the drug handling enterprises that passed GSP authentication.METHODS:Targeted at part of GSP authentication-passed drug handling enterprises in Shanxi province,research methods like interview,direct observation,questionnaires etc.were adopted in the study.RESULTS&CONCLUSION:Some items in the current GSP need to be further specified and quantified.The GSP authentication should be conducted in strata.Drugs handling enterprises should emphasis the training of staffs to improve their comprehensive qualities,utilize and improve hard-ware facilities to improve business running conditions and warehouse conditions,strengthen the checking system through the evolvement of quality management rules and post responsibility regulations and to strengthen drug handling enterprises’man-agement on drug sources.

OBJECTIVE:To put forward the developing direction of drug managing enterprises in order to provide the reference for the governmental polices.METHODS:A field investigation was carried out in Shannxi province to analyze the problems existing in the drug managing enterprises after GSP authentication.RESULTS&CONCLUSION:Multielement,linkage,large scale,standardization,consideration,and information all constitute important factors in the development of drug managing enterprises.

Background and objective Despite undergoing curative resection, the 5-year survival rate for stage III non-small cell lung cancer (NSCLC) patients is less than 25%. hTere is a need for biomarkers for prediction of survival and guiding individual therapy. MiR-155 is one of most commonly upregulated miRNAs in malignancies, and regulates multiple pro-oncogenic pathways. We aimed to investigate the prognostic impact of miR-155 in resected stage III NSCLC patients. Methods Tumor formalin-ifxed, paraffn-embedded (FFPE) from 162 resected stage III NSCLC patients were collected. Total RNA including miRNA was extracted, and qRT-PCR was used to determine the expression of miR-155. Results Spearman rank correlation test showed a positive correlation between miR-155 expression and nodal status (r=0.169, P=0.032). MiR-155 expression had a signiifcant prognostic impact in the total cohort (P<0.001), in squamous cell carcinomas (P=0.002) and in adenocarcinomas (P=0.003). In N0-1 subgroup, miR-155 expression did not have a signiifcant prognostic on overall survival in univariate analysis (P=0.319). In N2 subgroup, miR-155 had a negative prognostic effect on OS in univariate analysis (P<0.001). Cox regression analysis revealed that miR-155 expression was unfavorable prognostic factors of OS (RR=2.311, 95%CI:1.479-3.611, P<0.001). Conclusion High expression of miR-155 represents a valuable marker of poor clinical outcomes in patients with stage III NSCLC.